share_log

Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Increases By 2,468.9%

kopsource ·  Dec 29, 2022 02:11

Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 156,700 shares, a growth of 2,468.9% from the November 30th total of 6,100 shares. Based on an average daily trading volume, of 745,200 shares, the short-interest ratio is currently 0.2 days.

Q BioMed Price Performance

Shares of QBIO traded down $0.00 during mid-day trading on Wednesday, hitting $0.01. 642,508 shares of the company's stock were exchanged, compared to its average volume of 443,292. Q BioMed has a 52 week low of $0.01 and a 52 week high of $0.58. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.03.

Get Q BioMed alerts:

Q BioMed (OTCMKTS:QBIO – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.

About Q BioMed

(Get Rating)

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.

See Also

  • Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
  • The Top Three Stocks Analysts Say To Buy
  • Can Dick's Sporting Goods Stock Score Another Win In Q4?
  • Yum! Brands Looks Tasty in 2023
  • Why Did Immutep Ltd Stock Soar Recently?
  • 3 Industrial Stocks to Help Build Your 2023 Watchlist

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment